This site is for US residents only

GEOMETRYmono-1: Phase II Trial of INC280

Capmatinib (INC280)

A Phase II study for people with non-small cell lung cancer (NSCLC) that harbors a MET mutation and/or amplification

Call me back

For more information about Signature trials, enter your contact details and a representative will call you at your convenience.

*Required Information

*First Name
*Last Name
*Phone Number
*Zip Code
*Preferred time to call
*Time zone

Your email has been successfully sent

There was an error while sending your email

Call Now


We are here to answer any questions you may have about participating in a Signature trial.

Trial Goal

To learn whether capmatinib (INC280) displays safe and effective antitumor activity in treating NSCLC in patients who have received 1 or 2 prior systemic therapies for their advanced cancer.

You may be eligible to participate if you

  • Have advanced NSCLC and have been treated for it
  • Have both confirmed EGFR wild-type and ALK-negative NSCLC
  • Have, as determined by a Novartis-approved laboratory, either c-MET amplification or c-MET mutation
  • Are 18 years of age or older
  • Meet other eligibility criteria

Depending on the type of tumor you have and/or prior treatments, you may not be eligible for this clinical trial. Please speak to your doctor. This clinical trial may close at any time.

Download the Doctor Discussion Guide